Modality
Fusion Protein
MOA
ALKi
Target
MET
Pathway
Wnt
WMCervical CaACC
Development Pipeline
Preclinical
~Dec 2021
→ ~Mar 2023
Phase 1
~Jun 2023
→ ~Sep 2024
Phase 2
Dec 2024
→ Sep 2025
Phase 2Current
NCT05408088
313 pts·Cervical Ca
2024-12→2025-09·Completed
313 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-09-147mo agoPh2 Data· Cervical Ca
Trial Timeline
2025Q2Q3
P2
Complet…
Catalysts
Ph2 Data
2025-09-14 · 7mo ago
Cervical Ca
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05408088 | Phase 2 | Cervical Ca | Completed | 313 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| ALN-3284 | Alnylam | Phase 2/3 | CDK2 |